Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Carbohydrate sulfotransferase 1 (CHST1)
- Target
- CHST1
- Molecular classification
- Enzyme, Sulfotransferase, Membrane-associated enzyme (Golgi localized)
01
Overview
Carbohydrate sulfotransferase 1 (CHST1) is a Golgi-localized, membrane-bound enzyme that transfers a sulfate group from 3'-phosphoadenosine-5'-phosphosulfate (PAPS) to the 6-position of internal galactose residues on keratan sulfate chains, contributing to the biosynthesis and elongation of keratan sulfate proteoglycans in tissues such as cornea and brain. Its enzymatic activity influences extracellular matrix properties, cellular adhesion, and signaling, and it is implicated in connective tissue disorders and certain cancers, where altered expression serves as a potential disease marker.
- Other names
- C6STGST-1KS6STKSGal6STKSSTKeratan sulfate Gal-6 sulfotransferaseKeratan sulfotransferaseGalactose/N-acetylglucosamine/N-acetylglucosamine 6-O-sulfotransferase 1carbohydrate (chondroitin 6/keratan) sulfotransferase 1carbohydrate (keratan sulfate Gal-6) sulfotransferase 1
02
Mechanism of action
Not applicable; as above, no targeted drugs known. Theoretical: inhibitors would block 6-O-sulfation of galactose, altering glycan-mediated cell interactions.
03
Biological functions
Catalyzes sulfation of internal galactose residues of keratan sulfate and related glycoconjugatesBiosynthesis and elongation of keratan sulfate (a glycosaminoglycan in proteoglycans)Construction of O-linked glycans with 6-sulfoGalbeta motifsParticipates in formation of extracellular matrix proteoglycans important for cell communication, especially in brain development and lymph node high endothelial venulesContributes to immune cell trafficking through the biosynthesis of specific glycan motifs
04
Disease associations
Connective tissue disorders, especially macular corneal dystrophyCancer (overexpression linked to tumor progression, diagnostic and prognostic marker in malignancies)Inflammation (involved in leukocyte trafficking and tissue remodeling)
05
Safety considerations
Inhibition could disrupt normal keratan sulfate biosynthesis, potentially leading to corneal and cartilage pathologyChallenge: Substrate overlap among sulfotransferases may cause off-target effects if enzymes are pharmacologically inhibited
06
Interacting drugs
No specific drugs directly target CHST1 identified in current literature or standard pharmacological databases. Glycosaminoglycan pathway inhibitors may have indirect effect, but no direct clinical agent is currently known.
07
Biomarkers
Increased tissue/cellular expression used as diagnostic/prognostic biomarker in certain cancers and connective tissue disorders (not widely established as clinical biomarker)
Beyond the preview
Go deeper on Carbohydrate sulfotransferase 1 (CHST1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Carbohydrate sulfotransferase 1 (CHST1).